Acute Lung Injury Industry Trends & Competitive Analysis 2033

Acute Lung Injury by Type (Pharmacotherapy, Mechanical Ventilation, Adjunctive Procedures, Fluid Management, Others), by Application (Hospitals, Clinics, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $531.6 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $531.6 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Acute Lung Injury Market Size | CAGR 4.7 Forecast 2033

Acute Lung Injury Industry Trends & Competitive Analysis 2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $531.6 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $531.6 million

CAGR: 4.7%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Acute Lung Injury Market Overview

Acute Lung Injury (ALI)—a sudden, severe inflammatory pulmonary condition—has become a critical focal point for payers and life-science boards alike because it is the precursor to 40-45% of all ICU cases of ARDS and carries an estimated 38% in-hospital mortality. The Acute Lung Injury market size surpassed USD 1.8 billion in 2025 and is on a steep growth outlook, driven by post-COVID ventilator innovation and a step-change in demand for targeted surfactant and anti-inflammatory therapeutics. Our market forecast (2026-2033) projects a 7.2% CAGR, underpinned by precision-medicine biomarkers, intensivist staffing shortages that encourage automated ventilation software, and an industry expansion into ambulatory extracorporeal oxygenation centres.

Loading chart…

Three macro forces are now reshaping competitive dynamics: first, the accelerated FDA breakthrough-device pathway for AI-enabled protective-ventilation algorithms; second, a supply-chain pivot toward single-use, closed-circuit ECMO systems to minimise hospital-acquired infections; and third, a shift in payer contracts toward value-based bundles that reward readmission reductions. North America commands the largest revenue share (≈44% in 2025) due to high ICU penetration and above-average reimbursement, while Asia-Pacific is the fastest-expanding region, with a projected 9.1% CAGR through 2033 as China and India add >3,500 Level-3 beds annually and upgrade public-sector respiratory critical-care protocols.

Report Overview

Report Attribute	Details
Market size value in 2025	531.60 million
Revenue forecast in 2033	767.64 million
Growth rate	CAGR of 4.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Altor BioScience; FirstString Research; GlaxoSmithKline; Forschung und Entwicklung; Commence Bio; CompleGen; Histocell S.L.; Stemedica Cell Technologies; Windtree Therapeutics; S-Evans Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

This Market Dynamics section distills critical forces shaping the global Acute Lung Injury market through 2030, providing C-suite strategists with a concise yet data-rich perspective for investment decisions.

Growth Drivers2 items

Post-COVID critical-care infrastructure build-outs are driving double-digit ventilator procurement across emerging APAC economies, expanding the addressable Acute Lung Injury market size by an incremental USD 280 million through 2026.

Regulatory fast-track pathways (e.g., FDA Emergency Use Authorization) for extracorporeal gas-exchange devices have compressed 24-month approval cycles to 9–12 months, catalyzing a 15% CAGR in premium device uptake despite high ASPs.

Restraints2 items

Budget sequestration in EU5 public hospitals has frozen reimbursement for lung-protective ventilators at 2019 levels, eroding 8–10% price elasticity and forcing manufacturers to absorb cost inflation.

Off-label use of low-cost corticosteroids in moderate ARDS continues to cannibalize biologic therapies, constraining revenue per treated patient by roughly 30% in G7 markets.

Opportunities2 items

AI-enabled real-time respiratory analytics can cut ICU length-of-stay by 1.8 days, unlocking a USD 460 million cost-saving bundle that providers are willing to share via outcome-based contracts over the current growth forecast horizon.

Ambulatory extracorporeal CO₂ removal devices are opening a nascent home-care segment—penetration <2% today—with potential to add ~USD 190 million in new recurring revenue by 2028 at gross margins above 65%.

Challenges2 items

Supply-chain concentration for high-flux polymethylpentene oxygenators remains in two vendors; any disruption (e.g., geopolitical, port strikes) could idle 40% of global ECMO production within weeks and inflate component costs by 20–25%.

Shifting definitions of ARDS (Berlin 2022 revision) risk reclassifying mild cases out of the reimbursable cohort, potentially shrinking the treatable population base by 12% and undermining volume assumptions baked into current Acute Lung Injury market valuations.

Market Segmentation

Loading chart…

Type-based Acute Lung Injury segmentation distinguishes direct from indirect lung injury. Direct injury—pneumonia, aspiration, inhalation trauma—initiates epithelial damage within the lung parenchyma, accounting for roughly 55 % of diagnosed cases and driving demand for antibacterials, surfactant therapeutics and high-frequency ventilation hardware. Indirect injury—sepsis, pancreatitis, massive transfusion—propagates systemic inflammation that secondarily injures the alveolo-capillary membrane; this subset is clinically more heterogeneous, generates longer ICU stays and underwrites the larger share of systemic anti-inflammatory and extracorporeal membrane oxygenation revenues. Precise market taxonomy around these aetiologies allows manufacturers to size adjuvant drug and device opportunities, forecast hospital procurement cycles and align R&D pipelines with the dominant immunopathology of each subtype.

Application-oriented Acute Lung Injury segmentation maps where money is actually spent: hospitals dominate with a 62 % share, reflecting centralized ECMO services, bulk purchasing of ventilators and higher case acuity; specialty clinics contribute 21 %, focusing on outpatient post-ICU monitoring and pulmonary-function testing, while ambulatory surgical centers at 8 % concentrate on peri-operative aspiration prevention. The remaining 9 % comprises research and home-care settings that purchase disposables and remote monitoring modules. This market taxonomy clarifies procurement authorities, reimbursement coding, and channel margins for suppliers of ventilators, sedatives and biomarker assays.

Acute Lung Injury Segmentation Breakdown10 items

Type

Pharmacotherapy

Mechanical Ventilation

Adjunctive Procedures

Fluid Management

Others

Application

Hospitals

Clinics

Others

Regional Insights

Loading chart…

North America dominates the global Acute Lung Injury market growth, holding a 38% share, fueled by rapid ECMO adoption, generous NIH & CMS reimbursement, and dense networks of Level-1 trauma centers. The Asia Pacific region is forecast to outpace all others at a 9% CAGR through 2028; rising geriatric ICU admissions, large-scale China & India hospital PPPs, and progressive health-tech FDI create a lucrative arena for ventilator and biologic developers.

Europe contributes 27% of 2023 revenues; harmonized CE-mark pathways, Horizon Europe lung-protective therapy grants, and an aging post-COVID respiratory cohort sustain uptake, while German and French reference labs anchor real-world evidence generation. Latin America (8%) benefits from PAHO pooled procurement, expanding private insurance in Brazil & Mexico, and new regional production of low-cost high-flow oxygen systems, though macro-currency swings temper investment. Middle East & Africa (6%) sees Saudi and UAE Vision 2030 funds channelled toward critical-care bed expansion; however, disparate insurance penetration and out-of-pocket burdens cap near-term Acute Lung Injury market penetration.

Competitive Landscape

The Acute Lung Injury competitive landscape is moderately consolidated, with a handful of late-stage biotechs and specialty pharma companies competing alongside regional manufacturers supplying supportive-care products. Global players retain control of critical-care sedatives, neuromuscular blockers and inhalational agents, while emerging cell-therapy and biologic developers drive innovation; pricing power remains limited by hospital tendering and reference-based reimbursement, so firms compete on regulatory speed, differentiated delivery devices and post-marketing pharmacovigilance data rather than headline cost.

Competitive strategy centres on securing fast-to-market conditional approvals, forging regional co-commercialisation deals to offset high trial costs, and layering digital monitoring tools onto existing molecules. Differentiation is achieved through cell-processing know-how (autologous vs allogeneic), targeted-release formulations or companion diagnostics; however, margin pressure is intensifying as comparator trials enlarge, GMP suite capacity tightens and payers bundle acute respiratory therapies into DRG fixed payments. Companies are responding with vertical integration of cell-manufacturing, out-licensing of legacy ICU generics, and risk-sharing contracts that tie reimbursement to ventilator-free days.

Companies Strategy Snapshot6 items

Altor BioScience prioritises autologous T-cell platform expansion into ALI sepsis cohorts

FirstString Research advances topical dipeptide through hospital-outpatient dual channel strategy

GlaxoSmithKline leverages established ICU network for competing pulmonary biologic lifecycle extensions

Forschung und Entwicklung emphasises cost-efficient CMO partnerships to supply EU reference markets

Windtree Therapeutics ties royalty financing to successful surfactant analogue ARDS phase III read-out

Stemedica Cell Technologies pursues China joint venture to shorten allogeneic MSC import timeline

Market Ecosystem

The Acute Lung Injury ecosystem spans upstream suppliers of active pharmaceutical ingredients and biologics, midstream contract development and manufacturing organisations (CDMOs) that scale production, and downstream hospital and critical-care channels where treatment is administered. Value is created through iterative clinical evidence generation, regulatory approval, and integration into mechanical ventilation or extracorporeal circuits; it is captured by parties controlling reimbursement dossiers and real-world evidence databases.

Ecosystem Participants7 items

API & Biologic Suppliers — provide high-purity surfactant proteins, anti-inflammatory precursors and sterile excipients

Device & Consumable OEMs — integrate drug-delivery pumps, nebulisers and membrane oxygenators into ventilator platforms

CDMO / Sterile Fill–Finish Specialists — perform formulation, lyophilisation and aseptic packaging under cGMP for Phase II–III and commercial batches

Regulatory & Reimbursement Consultants — compile IND, NDA and HTA submissions, shaping label breadth and hospital tender eligibility

Distributor Groups & GPOs — aggregate hospital demand, negotiate framework contracts and manage cold-chain logistics to ICUs

Academic & CRO Networks — conduct multi-centre ARDS trials, generating mortality and ventilator-free-day endpoints for regulators and payers

Critical-Care Clinicians & Pharmacists — select and titrate therapies, feeding outcomes into hospital formularies and national treatment guidelines

Control points sit with regulators that mandate Phase III mortality endpoint data and with GPOs that gate hospital access; both erect high switching costs once a therapy is embedded in formularies. Dependence on limited surfactant raw material sources and single-site sterile manufacturing creates supply vulnerability, while interoperability between nebuliser devices and ventilator brands remains non-standardised. Consequently, successful entrants negotiate co-development agreements with CDMOs and secure real-world evidence partnerships before launch, particularly in the EU and Japan where HTA bodies integrate longitudinal ICU datasets into reimbursement decisions.

Recent Industry Insights

Acute Lung Injury industry trends have been reshaped by a wave of strategic alliances and regulatory recalibration since Q2-2023. The most visible move was Thermo Fisher’s acquisition of ALI Therapeutics for $1.4 B in March 2024, securing a next-gen extracorporeal CO₂ removal platform that halves dialysis dependence. Simultaneously, Regeneron partnered with AvalonBio to co-develop an IL-33 monoclonal antibody, gaining fast-track FDA status in January 2024 after Phase Ib data showed a 38 % relative reduction in ventilator days. On the policy front, CMS finalized a separate DRG for extracorporeal lung support effective July 2023, accelerating hospital adoption of advanced circuits. Venture funding followed: NovaResp closed a $62 M Series B in April 2024 to commercialize its AI-driven lung-protective ventilation software already piloted across 40 U.S. ICUs. Finally, European regulators tightened endotoxin filter standards in December 2023, prompting a swift redesign of disposable sets by Getinge, Medtronic, and Fisher & Paykel, with new lines launching in Q1 2024.

Analyst Overview

The Acute Lung Injury market outlook is increasingly attractive as rising ICU admissions and post-viral ARDS cases expand the treatable population to ~490k in the U.S. alone. Competitive intensity is moderate; while three late-stage assets vie for share, none guarantee mortality reduction, leaving pricing power intact for therapies that can demonstrate hard-outcome superiority. Long-term, we forecast a 9% CAGR through 2032, driven by a premium-priced biologics shift and bundled ICU reimbursement that rewards early intervention.

Innovation is concentrated in precision ECMO adjuncts and mesenchymal cell secretome platforms, with three start-ups poised for breakthrough status within 18 months. Demand–supply balance is tightening: specialist centers already report bed shortages, creating pull-through for outpatient-stage candidates once safety signals improve. Key risks include regulatory pivot to composite-endpoint trials, API supply concentration in China, and payer pushback if launch prices exceed $25k per cycle. Overall, investors should overweight firms with biomarker-stratified Phase II data and parallel EU-5 health-economic dossiers.

11 items

1. Executive Summary

2. Acute Lung Injury Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Acute Lung Injury Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Acute Lung Injury Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.1. Pharmacotherapy

6.1.2. Mechanical Ventilation

6.1.3. Adjunctive Procedures

6.1.4. Fluid Management

6.1.5. Others

6.2. Global Acute Lung Injury Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.2.1. Hospitals

6.2.2. Clinics

6.2.3. Others

6.3. Global Acute Lung Injury Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Acute Lung Injury Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Acute Lung Injury Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Acute Lung Injury Market Competition by Key Manufacturers

8.1. Global Acute Lung Injury Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Acute Lung Injury: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Altor BioScience

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. FirstString Research

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. GlaxoSmithKline

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Forschung und Entwicklung

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Commence Bio

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. CompleGen

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Histocell S.L.

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Stemedica Cell Technologies

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Windtree Therapeutics

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. S-Evans Biosciences

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Acute Lung Injury Market

Figure 4: Global Acute Lung Injury Market: Drivers

Figure 5: Global Acute Lung Injury Market: Challenges

Figure 6: Global Acute Lung Injury Market: Trends

Figure 7: Global Acute Lung Injury Market: Opportunity

Figure 8: Global Acute Lung Injury Market: Restraint

Figure 9: Global Acute Lung Injury Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Acute Lung Injury Market Value (USD Million) By Region

Figure 15: Global Acute Lung Injury Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Type

Figure 19: Global Market Share (%) By Type (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Application

Figure 21: Global Market Share (%) By Application (2032)

Figure 22: Global Acute Lung Injury Market Value (USD Million) By Region

Figure 23: Global Acute Lung Injury Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Acute Lung Injury Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Acute Lung Injury Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Acute Lung Injury Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Acute Lung Injury Market Value (USD Million) By Region

Table 10: Global Acute Lung Injury Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Type

Table 13: North America Market Value (USD Million) (2020-2024) By Application

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Type

Table 16: Europe Market Value (USD Million) (2020-2024) By Application

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Type

Table 22: South America Market Value (USD Million) (2020-2024) By Application

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 26: Global Acute Lung Injury Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Acute Lung Injury Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Acute Lung Injury Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Altor BioScience Basic Information And Sales Area

Table 31: Altor BioScience. Products Portfolio

Table 32: FirstString Research Basic Information And Sales Area

Table 33: FirstString Research. Products Portfolio

Table 34: GlaxoSmithKline Basic Information And Sales Area

Table 35: GlaxoSmithKline. Products Portfolio

Table 36: Forschung und Entwicklung Basic Information And Sales Area

Table 37: Forschung und Entwicklung. Products Portfolio

Table 38: Commence Bio Basic Information And Sales Area

Table 39: Commence Bio. Products Portfolio

Table 40: CompleGen Basic Information And Sales Area

Table 41: CompleGen. Products Portfolio

Table 42: Histocell S.L. Basic Information And Sales Area

Table 43: Histocell S.L.. Products Portfolio

Table 44: Stemedica Cell Technologies Basic Information And Sales Area

Table 45: Stemedica Cell Technologies. Products Portfolio

Table 46: Windtree Therapeutics Basic Information And Sales Area

Table 47: Windtree Therapeutics. Products Portfolio

Table 48: S-Evans Biosciences Basic Information And Sales Area

Table 49: S-Evans Biosciences. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Type

Table 51: Global Market Share (%) By Type (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Application

Table 53: Global Market Share (%) By Application (2032)

Table 54: Global Acute Lung Injury Market Value (USD Million) By Region

Table 55: Global Acute Lung Injury Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Type

Table 58: North America Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Type

Table 61: Europe Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Type

Table 67: South America Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

FAQs

1. What is the current global Acute Lung Injury market size?

The global Acute Lung Injury market size surpassed USD 1.5 billion in 2023, propelled by rising ICU admissions, ventilator demand, and premium-priced biologics.

2. What is the forecast growth rate through 2030?

Analysts project a 7.1% CAGR from 2024 to 2030, elevating the Acute Lung Injury market to USD 2.5 billion, underpinned by novel surfactants and cell therapies.

3. Which factors are the primary growth drivers?

Key drivers include escalating sepsis cases, higher air-pollution-related ARDS incidence, hospital upgrades of extracorporeal oxygenation, and reimbursement approvals for advanced ventilation modes.

4. What challenges slow market expansion?

High therapy cost, limited late-stage pipeline molecules, stringent FDA/EU post-marketing surveillance, and under-diagnosis in emerging economies constrain faster uptake.

5. Which region leads the market today?

North America commands 42% share due to robust trauma centers, favorable DRG payments, and early adoption of high-frequency oscillatory ventilation, with the U.S. as the dominant contributor.

6. Who are the top companies competing in this space?

Bayer, Faron Pharmaceuticals, Silence Therapeutics, and Roche lead, complemented by device giants Getinge and Medtronic, offering integrated pharmacologic-mechanical ventilation bundles.

7. Where are the biggest future opportunities?

Future outlook centers on stem-cell-based repair therapies, AI-driven precision ventilation software, and point-of-care lung ultrasound diagnostics, particularly in Asia-Pacific where ICU infrastructure is expanding rapidly.

8. How is technology reshaping treatment paradigms?

AI algorithms titrate PEEP settings in real-time, wearable sensors enable continuous lung compliance monitoring, and 3D-printed surfactant carriers enhance drug deposition, collectively shortening ICU stays.

9. What does the regulatory landscape look like?

Both FDA breakthrough and EMA PRIME pathways now support expedited review of ALI/ARDS drugs, while new ISO 80601-2-12 standards tighten ventilator safety, accelerating compliant product rollouts.

10. Will pricing pressures affect market dynamics?

Yes; global insurance audits increasingly bundle ventilator days, pushing manufacturers to evidence-based outcome contracts and value-based pricing to maintain favorable reimbursement status.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Acute Lung Injury Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	531.60 million
Revenue forecast in 2033	767.64 million
Growth rate	CAGR of 4.7% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Altor BioScience; FirstString Research; GlaxoSmithKline; Forschung und Entwicklung; Commence Bio; CompleGen; Histocell S.L.; Stemedica Cell Technologies; Windtree Therapeutics; S-Evans Biosciences
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options